AD_____

GRANT NUMBER DAMD17-96-1-6062

TITLE: Biological Roles of Map K Cascades in Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Xiaohong Liu, Ph.D.
Michael Karin, Ph.D.

CONTRACTING ORGANIZATION: University of California, San Diego
La Jolla, CA 92093

REPORT DATE: August 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19971230 032

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 1997	Annual (1 Aug 96 - 31 Jul 97)

4. TITLE AND SUBTITLE Biological Roles of Map K Cascades in Breast Cancer Cells

5. FUNDING NUMBERS
DAMD17-96-1-6062

6. AUTHOR(S)
Xiaohong Liu, Ph.D.
Michael Karin, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of California
La Jolla, CA 92093

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200*

The purpose of this project is to better understand the signal transduction pathways that mediate growth inhibition of breast cancer cells. In fibroblasts, the classical MAPK pathway (Ras/Raf-1/MEK/ERK) mediates the proliferative response by growth factors; while the novel MAPK pathway (Ras/Rac/MEKK1/JNKK1/JNK) may be involved in growth inhibition. A growth factor receptor ErbB-2, which is a critical regulator of the growth and differentiation of breast cells, is overexpressed in 25% of human mammary tumors. Interestingly, its ligand NDF (neu differentiation factor) can either induce the proliferation or differentiation of breast cancer cells. Using mammary carcinoma cells, which proliferate or differentiate upon NDF addition, the respective roles of the two MAPK cascades in controlling cell growth and differentiation are examined. As demonstrated in this report, both the JNK and the ERK cascades are activated at similar kinetics in the differentiative AU565 and the proliferative SKBR3 cells. However, JNK is marginally activated in the proliferative MCF7 cells and not activated in the differentiative MDAMB453 cells. In contrast, ERK is strongly activated by NDF in MCF7 cells, while it is only moderately activated in MDAMB453 cells. Thus, no correlation has been found between the activation profile of the JNK and ERK cascades and the growth responses of the above four mammary carcinoma cells.

14. SUBJECT TERMS	15. NUMBER OF PAGES
Breast Cancer, Signal Transduction, MAP kinase, proliferation, differentiation, apoptosis, HRG (heregulin, neu differentiation factor, NDF)	16
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

__X__ Where copyrighted material is quoted, permission has been obtained to use such material.

__X__ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

__X__ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

__X__ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

__X__ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

__X__ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

__X__ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

8/29/97

PI - Signature Date

Table of Contents

INTRODUCTION

The focus of this report is to investigate the respective roles of different MAPK cascades in mediating distinct cellular responses to neu differentiation factor (NDF) in breast cancer cells. Specifically, whether the proliferative or the differentiative response to NDF in breast cancer cells is due to differential activation of the Raf-1/ERK or the MEKK1/JNK MAPK cascades.

In mammalian cells, the classical MAPK (mitogen-activated protein kinase or extracellular signal-regulated kinase, ERK) pathway (Ras/Raf-1/MEK/ERK) is an important mediator of the proliferative response in fibroblasts signaled by growth factors, although it has been reported that it could also induce the differentiation of certain cell types, such as PC12 pheochromocytoma cells (1-4). The ERKs are phosphorylated and activated by the MEKs (5). The MEKs in turn are phosphorylated and activated by Raf-1, which itself is activated by growth factor receptors via Ha-Ras (6-9). Recently, two novel MAPKs, JNK1 and JNK2 (Jun amino-terminal kinase or stress-activated protein kinase, SAPK) were identified and cloned (10-13). Instead of the MEKs, the JNKs are phosphorylated and activated by JNK kinases, one of which was molecularly cloned (JNKK1 or SEK1 or MKK4) (14-16). JNKK1, in turn, is not activated by Raf-1 but by another protein kinase called MEKK1 (15, 17). Although activation of MEKK1 is also Ras-dependent (18, 19), it does not occur through direct interaction. Recently, the small GTP binding protein Rac, a member of the Ras superfamily, was shown to act between Ras and MEKK1 (20). As Rac binds to the protein kinase PAK1 in a GTP-dependent manner and stimulates its autophosphorylation activity (21), PAK1 or a related kinase may mediate its effect on the JNK pathway through direct phosphorylation of MEKK1. Rac does not activate the ERK pathway (20). Therefore, Ras/Rac/MEKK1/JNKK1/JNK forms a novel MAPK pathway, independent of and separate from the classical Ras/Raf-1/MEK/ERK MAPK cascade. A schematic representation of the two signal transduction pathways initiated at growth factor receptors is shown.



The distinct protein kinase constituents and substrate specificities of the two MAPK pathways suggest that they may have different biological roles and mediate distinct cellular

responses (2). In addition to growth factors, the JNKs are also activated by a variety of stress signals, including UV irradiation, DNA damaging agents and tumor necrosis factor α (TNFα), which cause growth arrest or apoptosis rather than cell proliferation (10, 11, 12, 13, 15, 19). The pathways by which these stimuli activate the JNKs are not yet understood, and unlike the growth factor response, these pathways do not involve Ras or Rac (20). Recently, a proteolytic cascade has been implicated in apoptosis (22). However, it is not ruled out that MAPK cascades are also involved in transducing the death signal. Indeed, preliminary results suggest that selective activation of the MEKK1/JNK pathway inhibits PC12 cell proliferation and triggers apoptosis in NIH3T3 fibroblasts. In direct contrast, the ERKs are mainly activated by growth factors and in most cell types exhibit a very weak response to stress signals (13). Constitutive activation of the classical ERK cascade leads to cell transformation and, in some cases, to cell differentiation (1). Although activation of the JNK cascade may play an auxiliary role in such responses, recent results suggest that when activated without concomitant activation of the ERK cascade, the JNK cascade may transduce growth inhibitory signals and may even lead to cell death (23). Based on these results, it is tempting to speculate that preferential Raf-1/ERK activation results in cell proliferation; whereas preferential MEKK1/JNK activation may cause growth arrest, or even lead to induction of apoptosis in certain cells.

This proposal is therefore focused on the roles of the different MAPK cascades in mediating distinct growth responses and how the balance between these pathways maintains normal cell growth. Breast cancer cells offer an excellent model system for such studies. Approximately 25% of primary breast tumors overexpress the ErbB-2 protein, which is a close relative of the EGF receptor (EGFR) (24). Importantly, the activity of ErbB-2 directly correlates with clinical prognosis, and its inhibition results in reversion of mammary carcinomas (24, 25). Recently, a ligand involved in its activation called neu differentiation factor (NDF, or heregulin, HRG) was identified (26, 27). Interestingly, NDF appears to have dual growth regulatory properties. In some mammary carcinoma cell lines (e.g., AU-565 and MDA-MB453), activation of ErbB-2 by NDF blocks cell proliferation, and induces cell differentiation and growth arrest (24, 26). However, in other breast cancer cell lines (e.g., SKBR-3 and MCF-7), NDF stimulates cell proliferation (24, 27). Furthermore, NDF activates ErbB-2 only in mammary tumor cells but not in ovarian carcinomas or transfected fibroblasts, suggesting that auxiliary proteins are required for ErbB-2 activation (28). Recently, additional members of the ErbB family, ErbB-3 and ErbB-4, were identified to be the direct receptors for NDF (28). Binding of NDF to ErbB-3 or ErbB-4 induces heterodimerization with ErbB-2, followed by its phosphorylation and activation (28). Like EGFR, ErbB-3 can cooperate with ErbB-2 in neoplastic transformation (24, 28a). However, the biological function of ErbB-2/ErbB-4 heterodimer is not known. Therefore, it will be interesting to propose that activation of ErbB-2/ErbB-3 or ErbB-2/EGFR heterodimer signals a mitogenic response, whereas activation of ErbB-2/ErbB-4 heterodimer may be responsible for NDF-induced cell differentiation. Since all of the ErbB proteins are quite similar in their cytoplasmic domains (28), it is not clear how the activation of different heterodimers elicits distinct biological responses.

BODY

Assumptions:

The signaling pathways that mediate cellular responses to ErbB-2 activation are not well understood, but based on its similarity to the EGF receptor, are likely to involve ERK and JNK activation. It is tempting to speculate that preferential Raf-1/ERK activation results in cell proliferation; whereas preferential MEKK1/JNK activation may cause growth arrest, or even lead to induction of apoptosis. It is therefore of interest to examine whether the proliferative or the differentiative response to NDF in different breast cancer cells is due to differential activation of the ERK or the JNK cascades, respectively. Using mammary carcinoma cells, which either proliferate or differentiate in response to NDF, the respective roles of the Raf-1/ERK and the MEKK1/JNK pathways in the response to NDF could be examined. If the hypothesis is correct, I will expect to see that upon NDF binding, the Raf-1/ERK cascade will be preferentially activated in proliferation-response cells (SKBR-3 and MCF-7), whereas the MEKK1/JNK cascade will be preferentially activated in differentiation-response cells (AU-565 and MDA-MB453).

Experimental Methods and Procedures:

To address the above question, human mammary carcinoma cell lines SKBR-3 and MCF-7, which proliferate in response to NDF (24, 27); and AU-565 and MDA-MB453, which differentiate upon NDF binding (24, 26), will be used. Various NDF isoforms have been cloned (27, 29a). As the different isoforms don't seem to differ in their biological activities and the β isoforms display higher receptor binding affinities than the α isoforms (27, 29a), NDFβ1 will be used for the following studies. NDF, whenever mentioned below, will refer to NDFβ1.

Cells will be incubated in the presence or absence of 0.2 nM or 1 nM NDF for 5 or 15 min (26), after which whole cell extracts will be prepared. Activation of ERK and JNK will be examined by immune complex kinase assay using myelin basic protein (MBP) or GST-cJun (1-79) as substrates, respectively (19). Specifically, ERK2 will be immunoprecipitated by an anti-ERK2 antibody, followed by incubation with MBP in kinase buffer containing [γ-^{32}P]ATP at 30°C for 25 min. In parallel, JNK will be immunoprecipitated by an anti-JNK antibody, followed by incubation with GST-cJun (1-79) in the presence of [γ-^{32}P]ATP at 30°C for 25 min. Phosphorylated proteins will be separated by SDS-PAGE and visualized by autoradiography. Untreated cells will serve as a negative control to determine background kinase activities. Cells treated with EGF (100 ng/ml) will be used as a positive control for ERK activation, and cells exposed to UV irradiation (40 J/m^2 for 20 sec) will be used as a positive control for JNK activation. If the hypothesis is correct, I will expect to see that upon NDF binding, the Raf-1/ERK cascade will be preferentially activated in the proliferation-response cells (SKBR-3 and MCF-7), whereas the MEKK1/JNK cascade will be preferentially activated in the differentiation-response cells (AU-565 and MDA-MB453).

Results and Discussion:

As shown in the attached figures, both the JNK and the ERK cascades are activated at similar kinetics in the differentiative AU-565 and the proliferative SKBR-3 cells. However, JNK is marginally activated in the proliferative MCF-7 cells and not activated in the differentiative MDA-MB453 cells. In contrast, ERK is strongly activated by NDF in MCF-7 cells, while it is only moderately activated in MDA-MB453 cells. Thus, no correlation has been found between the activation profiles of the JNK and ERK cascades and the growth responses of the above four mammary carcinoma cells. The role of JNK and ERK signal transduction pathways in the growth control of breast cancer cells is not clear at this point, which requires further investigation. Only task 1 in the statement of work has been completed, the remaining objectives may help address the contribution of the JNK and ERK cascades in the proliferation and differentiation of mammary carcinoma cells.

Figure Legends

Figure 1. Time course and dose response of NDF-induced JNK activation in AU565 and SKBR3 cells. Cells were incubated in the presence or absence of 0.2 nM or 1 nM NDF for 5 or 15 min. After cell lysis, JNK activity was examined by immune complex kinase assay using GST-cJun (1-79) as substrate. JNK immunoprecipitated from UV irradiated or EGF treated cells was used as controls.

Figure 2. Time course and dose response of NDF-induced ERK activation in AU565 and SKBR3 cells. Cells were incubated in the presence or absence of 0.2 nM or 1 nM NDF for 5 or 15 min. After cell lysis, ERK activity was examined by immune complex kinase assay using MBP as substrate. ERK immunoprecipitated from UV irradiated or EGF treated cells was used as controls.

Figure 3. Time course and dose response of NDF-induced JNK activation in MCF7 and MDAMB453 cells. JNK activity was examined as described in Figure 1 legend except that MCF7 and MDAMB453 cells were used.

Figure 4. Time course and dose response of NDF-induced ERK activation in MCF7 and MDAMB453 cells. ERK activity was examined as described in Figure 2 legend except that MCF7 and MDAMB453 cells were used.

Time Course and Dose Response of NDF-induced JNK Activation in AU565 and SKBR3 Cells



Figure 1

Time Course and Dose Response of NDF-induced ERK Activation in AU565 and SKBR3 Cells



Figure 2

Time Course and Dose Response of NDF-induced JNK Activation in MCF7 and MDAMB453 Cells



Figure 3

Time Course and Dose Response of NDF-induced ERK Activation in MCF7 and MDAMB453 Cells



Figure 4

CONCLUSIONS

As no correlation was found between the activation profiles of the JNK and ERK cascades and the growth responses of the above four mammary carcinoma cells, the activation of JNK and ERK in response to NDF in the above four mammary carcinoma cells seems to be cell line dependent. However, selective inhibition of either pathway through generation of stable cell lines or small molecule inhibitors, as specified in tasks 3-5 in the statement of work will help clarify this issue.

References:

1. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J. (1994). Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852.
2. Karin, M. (1994). Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr. Opin. Cell. Biol. 6: 415-424.
3. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
4. Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
5. Crews, C. M., Alessandrini, A., and Erikson, R. L. (1992). The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258: 478-480.
6. Dent, P., Haser, W., Haystead, T. A. J., Vincent, L. A., Roberts, T. M., and Sturgill, T. W. (1992). Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257: 1404-1407.
7. Kyriakis, J. M., App, H., Zhang, X. F., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992). Raf-1 activates MAP kinase-kinase. Nature 358: 417-421.
8. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993). Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74: 205-214.
9. Zhang, X. F., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993). Normal and oncogenic p21 ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364: 308-313.
10. Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037.
11. Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. (1993). Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes & Dev. 7: 2135-2148.
12. Kallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Derijard, B., Moore, G., and Davis, R. J., and Karin, M. (1994). JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes & Dev. 8: 2996-3007.
13. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994). The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160.
14. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995). Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682-685.
15. Lin, A., Minden, A., Martinetto, H., Claret, F. -X., Lange-Carter, C., Mercurio, F., Johnson, G. L., and Karin, M. (1995). Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268: 286-290.
16. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994). Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372: 794-798.
17. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994). Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372: 798-800.
18. Lange-Carter, C. A. and Johnson, G. L. (1994). Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265: 1458-1461.
19. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994). Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266: 1719-1723.

20. Minden, A., Lin, A., Claret, F. -X., Abo, A., and Karin, M. (1995). Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157.
21. Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., Lim, L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367: 40-46.
22. Whyte, M. and Evan, G. (1995). The last cut is the deepest. Nature 376: 17-18.
23. White, M. A., Nicolette, C., Minden, A., Polverino, A., Aelst, L. V., Karin, M., and Wigler, M. H. (1995). Multiple Ras functions can contribute to mammalian cell transformation. Cell 80: 533-541.
24. Peles, E. and Yarden, Y. (1993). Neu and its ligands: from an oncogene to neural factors. BioEssays 15: 815-824.
25. Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Jr., and Ullrich, A., and Slamon, D. (1991). Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Imm. 11: 117-127.
26. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., and Yarden, Y. (1992). Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205-216.
27. Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Shepard, H. M., Kuang, W. J., Wood, W. I., Goeddel, D. V., and Vandlen, R. L. (1992). Identification of heregulin, a specific activator of p185 erbB2. Science 256: 1205-1210.
28. Carraway, K. L. and Cantley, L. C. (1994). A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5-8.
28a. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Di Fiore, P. P., and Kraus, M. H. (1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
29. Caelles, C. Helmberg, A., and Karin, M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
29a. Wen, D., Suggs, S. V., Karunagaran, D., Liu, N., Cupples, R. L., Luo, Y., Janssen, A. M., Ben-Baruch, N., Trollinger, D. B., Jacobsen, V. L., Meng, S. Y., Lu, H. S., Hu, S., Chang, D., Yang, W., Yanigahara, D., Koski, R. A., and Yarden, Y. (1994). Structural and functional aspects of the multiplicity of Neu Differentiation Factors. Mol. Cell. Biol. 14: 1909-1919.
30. Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992). Serum-, TPA-, and Ras-induced expression from AP-1/Ets-driven promoters requires Raf-1 kinase. Genes & Dev. 6: 545-556.
31. Karin, M., Haslinger, A., Holtgreve, H., Cathala, G., Slater, E., and Baxter, J. D. (1984). Activation of a heterologous promoter in response to dexamethasone and cadmium by metallothionein gene 5'-flanking DNA. Cell 36: 371-379.
32. Samuels, M. L., Weber, M. J., Bishop, M., and McMahon, M. (1993). Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. Mol. Cell. Biol. 13: 6241-6252.
33. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270: 7420-7426.
34. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, B. M., Livi, G. P., White, J. R., Adams, J. L., and Young P. R. (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
35. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. (1995). Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth-factor. J. Biol. Chem. 270: 13585-13588.